MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study)
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Letrozole (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms MATAO
Most Recent Events
- 06 May 2022 Study design published in the BMC Cancer
- 08 Jun 2021 Trial design has been presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 18 Feb 2021 Planned End Date changed from 1 Jul 2030 to 1 Oct 2030.